Noven Pharmaceuticals, Inc. Sustainability Profile
Noven Pharmaceuticals, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States and operates primarily in North America. Founded in 1987, Noven has established itself as a pioneer in transdermal drug delivery systems, focusing on innovative therapies for various medical conditions. The company’s core products include a range of transdermal patches that deliver medications effectively and conveniently, setting them apart in the market. Noven's commitment to research and development has led to significant milestones, including partnerships with major pharmaceutical companies to enhance treatment options. With a strong market position, Noven Pharmaceuticals continues to be recognised for its contributions to patient care, making strides in the development of unique therapeutic solutions that improve adherence and outcomes for patients.
DitchCarbon Score
How does Noven Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Noven Pharmaceuticals, Inc.'s score of 30 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Noven Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Hisamitsu Pharmaceutical Co., Inc., which may influence its climate commitments and reporting practices. While Noven Pharmaceuticals has not established its own reduction targets or climate pledges, it is important to note that emissions data and performance metrics may be inherited from its parent company, Hisamitsu Pharmaceutical Co., Inc. This relationship suggests that Noven could align with broader sustainability initiatives and targets set by Hisamitsu, although specific details on these initiatives are not provided. As of now, Noven Pharmaceuticals has not publicly committed to any Science-Based Targets Initiative (SBTi) reduction targets or other significant climate initiatives. The lack of specific emissions data and reduction commitments highlights an opportunity for Noven to enhance its sustainability profile and contribute to industry-wide efforts in reducing carbon emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,986,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,919,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 100,228,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Noven Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Noven Pharmaceuticals, Inc.'s Location?
Noven Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Noven Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 13% last year and decreased by approximately 11% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
Noven Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Noven Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
